<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="55392">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01989832</url>
  </required_header>
  <id_info>
    <org_study_id>I10007</org_study_id>
    <nct_id>NCT01989832</nct_id>
  </id_info>
  <brief_title>Pharmaco-economical Study in Kidney Transplantation</brief_title>
  <acronym>EPHEGREN</acronym>
  <official_title>Pharmaco-economical Study in Kidney Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Limoges</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Limoges</source>
  <oversight_info>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The prevalence of renal acute rejection in transplantation is reduced thanks to the
      optimized use of immunosuppressive drugs. However, graft survival at ten years has not
      improved since then; this may be explained in part by the toxicity of these drugs, viral
      infections, and other comorbidities (diabetes, cardiovascular diseases …).

      According to transplant center, strategies for the combination of immunosuppressive drugs
      are different, and probably involve a difference in the global cost of patient management.
      There is no recommendation in France to establish similar practices.

      EPHEGREN is an observational, prospective, multicentric, pharmacoeconomic study for the
      renal transplant patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">February 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Number of Death</measure>
    <time_frame>4 years</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>to examine nature, dose and exposure in immunosuppresseurs.</measure>
    <time_frame>4 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Renal Transplant</condition>
  <arm_group>
    <arm_group_label>Biological and clinical Data collected</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        renal transplant patients
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients in the first month of renal graft, or patients already included in an other
             epidemiological French study (EPIGREN) in the 0-6 month period

          -  Men of women aged more than 18 years

          -  Patients able to exercise in writing their informed and free consent to participate
             to the biological collection

          -  Patients not opposing to collect their medical data

          -  Patients registered with a social security system

          -  Patients able to complete the questionnaires

        Exclusion Criteria:

          -  Patients aged less than 18 years and patients under guardianship

          -  Patients with a follow-up at another center other than those part of the study
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Pierre MARQUET, MD</last_name>
    <phone>05 55 05 60 17</phone>
    <email>pierre.marquet@unilim.fr</email>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Limoges</city>
        <zip>87 042</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre MARQUET, MD</last_name>
      <phone>05 55 05 60 17</phone>
      <email>pierre.marquet@unilim.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <lastchanged_date>November 15, 2013</lastchanged_date>
  <firstreceived_date>November 4, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cohort</keyword>
  <keyword>pharmaco-economic</keyword>
  <keyword>kidney</keyword>
  <keyword>transplantation</keyword>
  <keyword>quality of life</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
